The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ESMO GI 2025 | Reflex molecular testing study aims to improve colorectal cancer treatment timing
Wing Kin Liu, PhD, Guy’s and St Thomas’ NHS Foundation Trust, London, UK, outlines an ongoing pilot study in South East London hospitals comparing reflex molecular testing with standard care for colorectal cancer patients, with the aim of having molecular results available for the first multidisciplinary team meeting and oncology appointments, enabling patients to receive optimal targeted therapy from their first treatment cycle based on actionable mutations. This interview took place at the European Society for Medical Oncology (ESMO) Gastrointestinal Cancer 2025 Congress in Barcelona, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.”
